Earlier this month, US President Joe Biden shocked the pharmaceutical industry with his declared support for an intellectual property waiver for COVID-19 vaccines.
In this special podcast, reporter Charlotte Kilpatrick moderates a debate between Komal Kalha, lead for IP and trade policy at the International Federation of Pharmaceutical Manufacturers & Associations; James Love, director of Knowledge Ecology International; and Gordon Harris, partner at Gowling WLG.
In this heated debate, guests discuss the flexibilities of the TRIPS Agreement, know-how gaps, and whether the waiver – if implemented – could undermine incentives for future pharmaceutical research.
To listen to the 30-minute debate, click the link below.
